Light microscopic autoradiography of the distribution of [3H]rauwolscine binding to alpha 2-adrenoceptors in rat kidney

Analgesia

Critical to reducing patient morbidity as well as heightened ethical awareness, alleviation of pain in animals has become integral to medical case management and surgical procedures. Pharmacotherapy is directed at peripheral nociceptors, primary and secondary spinal neurons, and pain-processing areas in the CNS. Accordingly, three primary pharmacologic strategies have evolved: drugs that bind to and activate opioid receptors, drugs that bind to and activate alpha 2 receptors, and drugs that reduce de novo prostaglandin synthesis. In horses, the two predominant types of pain encountered are musculoskeletal and visceral pain. Several factors must be considered when devising a therapeutic strategy, including the etiology of the painful event, desired duration of therapy (acute vs chronic), desire for sedation, and potential side effects and toxicity. Opioids and alpha 2 agonists are particularly effective for visceral pain associated with colic. Butorphanol remains the only commercially available opioid and provides superior visceral analgesia compared with pentazocine or flunixin meglumine but not compared with the alpha 2 agonists. The behavioral changes such the sedative effects of alpha 2 agonists and the increased locomotion and CNS excitability seen with some opioids are important considerations when these agents are used as analgesics. NSAIDs may be considered for visceral pain therapy also, especially pain associated with an inflammatory component or endotoxemia. In particular, flunixin meglumine and ketoprofen provide prolonged analgesia and suppress the effects of endotoxin. Long-term therapy of musculoskeletal diseases usually necessitates chronic NSAID use. Although many NSAIDs are now available in approved equine formulations, there remain some important differences among NSAIDs for the practitioner to consider when choosing an analgesic. NSAIDs differ in their ability to ameliorate pyrexia, affect platelet function, alleviate pain, and reduce inflammation. For ease of administration, those available for oral use include phenylbutazone, meclofenamic acid, flunixin meglumine, and naproxen. All are potentially ulcerogenic, and poor tolerance to one may necessitate switching to another with a better toleration profile or to drug from a different analgesic class.

Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alpha2-adrenoceptors

1 Atipamezole (4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole) was first introduced as a potent and specific alpha2-adrenoceptor antagonist, but in some tissues [3H]atipamezole identifies an additional population of binding sites, distinct from both classical alpha2-adrenoceptors and I1- and I2-imidazoline receptors identified with [3H]para-aminoclonidine or [3H]idazoxan. 2 In the present study we have characterized [3H]atipamezole binding sites in rat kidney by receptor autoradiography and membrane binding assays and determined whether they are pharmacologically identical with the previously described binding sites for [3H]para-aminoclonidine and [3H]idazoxan. [3H]RX821002 and [3H]rauwolscine were used to compare the regional distribution of alpha2-adrenoceptors to that of non-adrenergic binding sites of [3H]atipamezole. 3 Comparative autoradiographic experiments demonstrated the differential localisation of [3H]atipamezole, [3H]RX821002 and [3H]rauwolscine binding sites in rat kidney. The pattern of distribution of non-adrenergic [3H]atipamezole binding sites is clearly distinct from that of alpha2-adrenoceptors. 4 The non-adrenergic binding of [3H]atipamezole in rat kidney does not fall into any of the previously identified three classes of imidazoline receptors studied with [3H]para-aminoclonidine, [3H]idazoxan and [3H]RX821002. 5 Atipamezole had no inhibitory effect on MAO-A or MAO-B activity in renal membranes, which speaks against the involvement of MAOs in the observed radioligand binding.

Alpha2B adrenoceptor mRNA expression during rat brain development

The expression of alpha2B adrenoceptor mRNA in developing and adult rat brain was examined, using in situ hybridization with S-labeled riboprobes. In the adult we have detected more widespread expression than previously reported, with moderate to strong hybridization signals in the fundus striati, olfactory tubercles, septum, thalamus and Purkinje cells of the cerebellum. In addition, there was low expression in the endopiriform nucleus, claustrum, cortex, caudate-putamen and spinal trigeminal nucleus of the brain stem. During embryonic development, there was intense, transient mRNA expression in the developing vascular plexus and vasculature which disappeared by birth. In most brain areas which exhibit mRNA expression in the adult, expression started during late embryonic development; with the exception of the thalamus, where expression was differentially regulated in sensory and non-sensory thalamic nuclei starting at the end of the first postnatal week. In addition, there was transiently upregulated expression in the caudate-putamen and cerebellar Purkinje cells during late embryonic and early postnatal development, respectively. This transient expression correlates with the time of neuronal migration and differentiation in these structures and complements the developmental expression of alpha2A and alpha2C adrenoceptors. These results suggest that alpha2B adrenoceptors may play a role in angiogenesis and in mediating neurotrophic functions of norepinephrine in some brain areas.

Differential characteristics and localisation of [3H]oxazoline and [3H]imidazoline binding sites in rat kidney

Comparative autoradiography revealed that the imidazolines [3H]p-aminoclonidine and [3H]idazoxan labelled high densities of alpha 2A-adrenoceptor sites in the inner medulla and inner stripe of the outer medulla of rat kidney. In contrast, the oxazoline [3H]rilmenidine labelled a high density of non-adrenergic sites in the cortex and outer stripe of the outer medulla, a lower density in the inner stripe and inner medulla and a low density of alpha 2A-adrenoceptor sites in inner medulla. The existence of novel, non-adrenergic oxazoline sites of potential functional importance in rat kidney has important implications for the classification of imidazoline receptors.

Alpha-adrenoceptors

Major advances have been made in our understanding of the molecular structure and function of the alpha-adrenoceptors. Many new subtypes of the alpha-adrenoceptor have been identified recently through biochemical and pharmacological techniques and several of these receptors have been cloned and expressed in a variety of vector systems. Currently, at least seven subtypes of the alpha-adrenoceptor have been identified and the molecular structure and biochemical functions of these subtypes are beginning to be understood. The alpha-adrenoceptors belong to the super family of receptors that are coupled to guanine nucleotide regulatory proteins (G-proteins). A variety of G-proteins are involved in the coupling of the various alpha-adrenoceptor subtypes to intracellular second messenger systems, which ultimately produce the end-organ response. The mechanisms by which the alpha-adrenoceptor subtypes recognize different G-proteins, as well as the molecular interactions between receptors and G-proteins, are the topics of current research. Furthermore, the physiological and pathophysiological role that alpha-adrenoceptors play in homeostasis and in a variety of disease states is also being elucidated. These major advances made in alpha-adrenoceptor classification, molecular structure, physiologic function, second messenger systems and therapeutic relevance are the subject of this review.

Autoradiography of adrenoceptors in rat and human brain: alpha-adrenoceptor and idazoxan binding sites

This chapter reviews the current classification of adrenoceptors, and notes the difficulties of combining the molecular biological and pharmacological classifications of adrenoceptors. Possibilities for mapping the distribution of the proposed subtypes of adrenoceptors using currently available ligands are discussed, and the autoradiographic visualisation of the broad subtypes of alpha 1-, alpha 2-, beta 1-, and beta 2-adrenoceptors in the rat, monkey and human brain described and illustrated. The non-selectivity of ligands currently being used to label alpha-adrenoceptors is shown; we compare the distribution of [3H]idazoxan binding sites with the distribution of alpha 2-adrenoceptors visualised using other ligands. Resolution limitations of current autoradiographic approaches are considered and we shown how in situ hybridisation can complement data from receptor labelling studies used to localise receptors to pre- or postsynaptic sites.

Characterization of alpha 2-adrenoceptors in the rat: proximal tubule, renal membrane and whole kidney studies

In the present study, alpha 2-adrenoceptors have been characterized in rat renal proximal tubules which were isolated by a Percoll gradient technique. Competitive binding curves with [3H]rauwolscine (0.5 nM) and alpha 2-adrenoceptor agonists and antagonists were consistent with an alpha 2B-adrenoceptor subtype. However, the rank order of potency (Ki) for clonidine and UK 14,304 was reversed from that reported for other tissues (clonidine, 48 nM greater than UK 14,304, 330 nM). This rank order was confirmed in a crude renal membrane preparation consisting of whole kidney as well as separated medullary and cortical segments. An intrarenal infusion of clonidine at 11 nmol/kg per min resulted in a greater diuresis and natriuresis than an equimolar dose of UK 14,304 suggesting that clonidine also had a greater affinity in the collecting tubules. Further displacement studies in proximal tubules with [3H]rauwolscine and calcium channel blockers demonstrated that verapamil was the most potent (Ki, 2.3 microM), followed by diltiazem (48% displacement at 100 microM) and then nifedipine (no displacement at 100 microM). These studies indicated that alpha 2-adrenoceptor in the rat proximal tubule may be of the alpha 2B-adrenoceptor subtype. Further studies will be required to determine whether the reverse rank order of potency of clonidine and UK 14,304 is consistent with an alpha 2-adrenoceptor subtype which is different from that found in other tissue.

High NaCl diets increase alpha 2-adrenoceptors in renal cortex and medulla of NaCl-sensitive spontaneously hypertensive rats

Diets high in NaCl simultaneously elevate renal alpha 2-adrenoceptor binding and exacerbate hypertension in young NaCl-sensitive spontaneously hypertensive rats (SHR-S). The present study tests the hypothesis that in SHR-S on a high NaCl diet, an upregulation of renal alpha 2-adrenoceptors is present in densely innervated areas of the kidney, and this precedes the increase in blood pressure. Seven week old SHR-S fed on a high (8%) compared to basal (1%) NaCl diet for 2 weeks displayed significantly exacerbated hypertension and elevated renal alpha 2-adrenoceptor binding in both cortex and medulla. In contrast one week on the high NaCl diet did not alter renal alpha 2-adrenoceptor number or blood pressure in SHR-S. Autoradiographic experiments demonstrated that the NaCl-induced upregulation of alpha 2-adrenoceptors occurs in all areas of the renal cortex and medulla. None of these differences were observed in NaCl-resistant, Wistar-Kyoto rats (WKY). Further, the high NaCl diet did not alter renal alpha 1-adrenoceptor binding in SHR-S or WKY. Together with previous findings, these data suggest that the NaCl-induced upregulation of renal alpha 2-adrenoceptors is not specific to densely innervated regions of the kidney.

Renal nerve contribution to NaCl-exacerbated hypertension in spontaneously hypertensive rats

Previous studies demonstrate that bilateral renal denervation enhances urinary sodium excretion and delays the onset of hypertension in young (7-week-old) spontaneously hypertensive rats (SHR) maintained on ordinary laboratory chow. We interpret these data as suggesting that increased renal nerve activity in this model contributes to hypertension by causing excess sodium retention. More recent studies show that dietary NaCl supplementation increases blood pressure and peripheral sympathetic nervous system activity in NaCl-sensitive SHR (SHR-S). The present study tests the hypothesis that the renal nerves contribute to the rise in arterial pressure caused by dietary NaCl supplementation in this model. SHR-S were fed a high (8%) or basal (1%) NaCl diet beginning at age 7 weeks. Bilateral renal denervation was carried out 2 weeks after the initiation of the diets, at which time systolic blood pressure was significantly higher in the high (compared with the basal) NaCl group. Systolic blood pressure was reduced slightly less in denervated SHR-S on the high (compared with basal) NaCl diet during the following 5 weeks. Renal denervation performed 1 week before initiation of the diets attenuated the subsequent development of hypertension equally in both groups. Both renal denervation and the high NaCl diet increased alpha 2-adrenergic receptor numbers in the kidney; renal denervation caused an approximately equal increase in alpha 2-adrenergic receptor binding in SHR-S on high and basal NaCl diets. The high NaCl diet increased plasma noradrenaline concentration, and renal denervation lowered mean arterial pressure but did not decrease circulating catecholamines in either diet group.(ABSTRACT TRUNCATED AT 250 WORDS)

Alpha 2 adrenergic agonists stimulate Na+-H+ antiport activity in the rabbit renal proximal tubule

The role of adrenergic agents in augmenting proximal tubular salt and water flux, was studied in a preparation of freshly isolated rabbit renal proximal tubular cells in suspension. Norepinephrine (NE, 10(-5) M) increased sodium influx (JNa) 60 +/- 5% above control value. The alpha adrenergic antagonist, phentolamine (10(-5) M), inhibited the NE-induced enhanced JNa by 90 +/- 2%, while the beta adrenergic antagonist, propranolol, had a minimal inhibitory effect (10 +/- 2%). The alpha adrenergic subtype was further defined. Yohimbine (10(-5) M), an alpha2 adrenergic antagonist but not prazosin (10(-5) M), an alpha1 adrenergic antagonist completely blocked the NE induced increase in JNa. Clonidine, a partial alpha2 adrenergic agonist, increased JNa by 58 +/- 2% comparable to that observed with NE (10(-5) M). Yohimbine, but not prazosin, inhibited the clonidine-induced increase in JNa, confirming that alpha2 adrenergic receptors were involved. Additional alpha2 adrenergic agents, notably p-amino clonidine and alpha-methyl-norepinephrine, imparted a similar increase in JNa. The clonidine-induced increase in JNa could be completely blocked by the amiloride analogue, ethylisopropyl amiloride (EIPA, 10(-5) M). The transport pathway blocked by EIPA was partially inhibited by Li and cis H+, but stimulated by trans H+, consistent with Na+-H+ antiport. Radioligand binding studies using [3H]prazosin (alpha1 adrenergic antagonist) and [3H]rauwolscine (alpha2 adrenergic antagonist) were performed to complement the flux studies. Binding of [3H]prazosin to the cells was negligible. In contrast, [3H]rauwolscine showed saturable binding to a single class of sites, with Bmax 1678 +/- 143 binding sites/cell and KD 5.4 +/- 1.4 nM. In summary, in the isolated rabbit renal proximal tubular cell preparation, alpha2 adrenergic receptors are the predominant expression of alpha adreno-receptors, and in the absence of organic Na+-cotransported solutes, alpha2 adrenergic agonists enhance 22Na influx into the cell by stimulating the brush border membrane Na+-H+ exchange pathway.

Adrenoceptors in the kidney: localization and pharmacology

The kidney plays a key role in the regulation of blood pressure. The sympathetic nervous system can influence many aspects of kidney function in relation to blood pressure control, e.g. renal vascular tone, intrarenal renin release and tubular reabsorption of electrolytes and fluid. The intrarenal distribution of adrenoceptors has now been studied on the basis of modern receptor ligand binding techniques combined with microscopic studies. The preferential localization of each adrenoceptor subtype within the kidney is reviewed. Furthermore, an attempt is made to describe the functional correlation of the presence of different adrenoceptor subtypes. Finally, the possible role of renal adrenoceptor abnormalities in the pathogenesis of hypertension is discussed.

Autoradiographic evidence for a heterogeneous distribution of alpha 1-adrenoreceptors labelled by [3H] prazosin in rat, dog and human kidney

The selective alpha1-adrenoreceptor antagonist radioligand [3H] prazosin has been used to localize alpha1-adrenoreceptors in slide mounted sections of rat, dog and human kidney. The biochemical characteristics of [3H] prazosin binding to rat kidney sections were examined and found to be saturable, reversible, stereoselective, with a KD of 0.12 nM and Bmax of 6.72 +/- 0.2 fmoles/section. 3H Ultrofilm images of [3H] prazosin binding to rat, dog, and human kidney revealed binding to the vasculature but in the rat additional receptors were confined to the renal cortex. In the rat kidney autoradiography using emulsion coated coverslips showed that binding in the renal cortex was largely to proximal tubules. In all three species the autoradiographic studies support a role for alpha1-adrenoreceptors in control of renal blood flow. In the rat the location of alpha1-adrenoreceptors suggests that they can also have an important influence on fluid and electrolyte balance, gluconeogenesis and production of prostanoids.